Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized everolimus therapy in metastatic breast cancer
2023-505590-33-06Phase 2Authorised
- Sponsor
- Országos Onkológiai Intézet
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus in breast cancer (2 arms), sponsored by Országos Onkológiai Intézet. Planned start Mar 2025; status: authorised.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505590-33-06.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505590-33-06.